Henan Newland Pharmaceutical Co. Ltd. A (301277) — Cash Flow Quality Index
Henan Newland Pharmaceutical Co. Ltd. A (301277) has a Cash Flow Quality Index of 0.96x as of December 2025. Operating cash flow of CN¥116.94 Million is below net income of CN¥121.25 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore Henan Newland Pharmaceutical Co. Ltd. A (301277) total assets for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Henan Newland Pharmaceutical Co. Ltd. A Cash Flow Quality Index (2020–2025)
Historical Cash Flow Quality Index for Henan Newland Pharmaceutical Co. Ltd. A across 6 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 301277 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Henan Newland Pharmaceutical Co. Ltd. A (2020–2025)
Year-by-year earnings quality comparison for Henan Newland Pharmaceutical Co. Ltd. A. For live market cap and the full company financial profile, see Henan Newland Pharmaceutical Co. Ltd. A (301277) market capitalisation.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.96x | CN¥116.94 Million | CN¥121.25 Million | ▲ +32.1% |
| 2024 | 0.73x | CN¥126.76 Million | CN¥173.63 Million | ▼ -55.3% |
| 2023 | 1.63x | CN¥259.46 Million | CN¥158.98 Million | ▲ +160.6% |
| 2022 | 0.63x | CN¥82.85 Million | CN¥132.30 Million | ▲ +46.7% |
| 2021 | 0.43x | CN¥49.08 Million | CN¥114.98 Million | ▲ +5.7% |
| 2020 | 0.40x | CN¥47.86 Million | CN¥118.46 Million | — |